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Background: With the continuous improvement of surgery and chemotherapeutic treatments, many tumour
patients increasingly achieve long-term survival and can even be completely cured. However, platinum-containing
drugs, which are widely used to treat a variety of types of cancer, cause menstrual disorders and ovarian failure,
which in turn lead to infertility. Thus far, gonadotropin releasing hormone (GnRH) agonist (GnRHa) and antagonist
(GnRHant) are reported to act as protective agents of the ovary in chemotherapy through the inhibition of the
female gonadal axis. Nevertheless, they both have disadvantages that limit their use. GnRHa causes a flare-up effect
during the first week after administration, and no long-acting GnRHant agent is available. GnRHa combined with
GnRHant may prevent the flare-up effect of GnRHa and rapidly inhibit the female gonadal axis. Several clinical
studies with small sample sizes have reported controversial conclusions. In this strictly controlled animal study, we
investigated the advantages of combination treatment with GnRHa and GnRHant.
Methods: Rats aged 12 weeks were divided into six groups: Control, cisplatin (CDDP), GnRHa, GnRHant,
Combination (sht, short-term) and Combination (lng, long-term) of GnRHa and GnRHant. The last four groups
received Triptorelin (1 mg/kg·d, for 14 days), Cetrorelix (0.5 mg/kg·d, for 10 days), a combination of Triptorelin
(1 mg/kg·d, for 10 days) and Cetrorelix (0.5 mg/kg·d, for 10 days) in the long-term group and for 3 days in the
short-term group. The Control and CDDP groups received saline (1 ml/kg·d, for 10 day). Then, all groups apart from
the Control group received cisplatin (1 mg/kg·d, for 10 days), and the Control group received another 10 days of
saline as described above. Blood samples were collected to detect the serum levels of E2, LH and FSH. Observation
of oestrous cyclicity was also performed after drug administration. Finally, bilateral ovaries were collected for
histological study and follicle counting.
Results: We observed a flare-up effect in rats treated with GnRHa, but not in any of the combination groups. The
percentage of normal cyclicity increased from 0% in the CDDP group to 25.0%, 33.3%, 66.7% and 41.7%, in the
GnRHa, GnRHant, combination (lng) and combination (sht) groups, respectively. Pretreatment with GnRHa, GnRHant
and combination (lng) significantly protected the primordial follicles from destruction by preserving 57.6%, 63.4%,
87.1% and 60.4% of the follicles, respectively.
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Conclusions: The combination of a GnRH agonist with antagonist completely prevented the flare-up effect and
enhanced the protective effect of the ovary from cisplatin-induced gonadotoxicity in rats.
Keywords: GnRH agonist, GnRH antagonist, Chemotherapy, Ovarian protectionBackground
With the continuous improvement of surgical and
chemotherapeutic treatments, many tumour patients
achieve long-term survival and can even be completely
cured [1]. Platinum-containing anti-cancer drugs
are widely used to treat a variety of cancers, in-
cluding sarcomas, carcinomas, and lymphomas. Cis-
diamminedichloroplatinum (cisplatin, CDPP) is the first
and most representative drug in this class. Cisplatin-
based combination chemotherapy displays significant
antitumor activity against cancers of the testis, ovary,
head, neck and lung. The underlying mechanism is
mainly due to chemical bonding to DNA, leading to
crosslinking of the DNA, which induces cell apoptosis
[2,3]. However, cisplatin may also harm the granulosa
cells of the follicles, causing menstrual disorders and
acute or chronic ovarian failure, resulting in infertility
[4,5]. Gynaecological oncologists and researchers are
faced with the challenge of protecting ovaries from
damage caused by chemotherapy and improving the
quality of life for patients [6,7].
Natural gonadotropin-releasing hormone (GnRH) is a
short-acting decapeptide that is secreted by the hypo-
thalamus, which could induce the secretion of LH and
FSH in the pituitary gland [8]. A modification in the
6th and 10th amino acids of GnRH results in the GnRH
agonist (GnRHa), which has increased biological activ-
ity compared to natural GnRH. The inhibition of the fe-
male gonadal axis by GnRHa could reduce the damage
caused to primordial follicles by chemotherapeutic
agents [9]. Nevertheless, the initial flare-up effect that
occurs during the first week of GnRHa treatment limits
its use [10].
GnRH antagonist (GnRHant) is one of the deri-
vatives of GnRHa, and it has a significant protective
effect on ovarian function through a stronger and ra-
pid inhibition of the female gonadal axis. However, the
effect is short lived. No long-acting antagonist is avail-
able [9,11]. Several clinical studies with small sample
sizes have suggested that GnRHant combined with
GnRHa could prevent the flare-up effect of GnRHa
and rapidly inhibit the female gonadal axis [12-15].
However, it is difficult to obtain a strict negative
control in clinical studies. In the present study, using
animal models, we investigated the advantages of
combined treatment with GnRHa and GnRHant for
weakening the GnRHa-induced flare-up effect andprotecting the ovary from the damage induced by
CDPP.Methods
Animals
Sexually mature female Wistar rats (12 weeks old, bo-
dy weight 280±20 g) were obtained from the Disease
Prevention and Control Center of Hubei Province,
China, and housed under special pathogen-free condi-
tions. The animals were kept in individual plastic cages
with ad libitum access to full-price feed and water in a
temperature-controlled room (22±2°C) on a 12 h light,
12 h dark schedule. All of the experimental procedures
were performed at the experimental animal centre of
Tongji Medical College, Huazhong University of Sci-
ence and Technology (HUST), China, according to the
international ethical guidelines and with the approval of
the HUST Ethics Committee.Drug treatment
A total of 72 rats with normal oestrous cycles (4–5 -
days) were randomly divided into six groups: Control,
CDDP, GnRHa, GnRHant combination (lng, long-
term) and combination (sht, short-term). The con-
trol group received 1 ml/kg·d of saline for 20 days. The
CDDP group received 1 ml/kg·d of saline for 10 days
followed by 1 mg/kg·d of cisplatin (Qilu Pharma-
ceuticals Co. LTD, China) for 10 days. The GnRHa
group received depot injections of 1 mg/kg of Trip-
torelin (Diphereline, Beaufour-Ipsen Pharmaceutical
Co. LTD., Tianjin) followed two weeks later by 1 mg/
kg·d cisplatin for 10 days. The GnRHant group re-
ceived 0.5 mg/kg·d of Cetrorelix subcutaneously (Owto
biotech INC. China) for 10 days followed by 1 mg/kg·d
of cisplatin for 10 days. The combination (lng) group
received depot injection of 1 mg/kg of Triptorelin
in combination with 0.5 mg/kg·d of Cetrorelix for 10 -
days followed by cisplatin as mentioned above. The
combination (sht) group was only co-treated with
Cetrorelix for 3 days. All of the other agents were ad-
ministered intraperitoneally. Pretreatment with the
GnRH analogues was performed at 9 am every day,
and cisplatin was injected at 11 am because previous
studies have shown that the serum concentration of
Cetrorelix reached a peak 1–2 h after injection.
Li et al. Reproductive Biology and Endocrinology 2013, 11:16 Page 3 of 8
http://www.rbej.com/content/11/1/16Estradiol (E2), Luteinising Hormone (LH) and Follicle-
Stimulating Hormone (FSH) assays
Blood specimens were collected on the 1st, 3rd, 5th and
8th day of the treatment schedule through the orbital
vein. Serum levels of E2, LH and FSH were analysed by
radioactive assay kits (Beijing North Institute of Bio-
logical Technology, China) following the manufacturer’s
instructions.Observation of oestrous cyclicity
The oestrous cycle was monitored for 10 days after the
treatment. Smears were obtained by carefully inserting a
non-needle syringe into the vagina and flushing with ap-
proximately 0.2 ml saline. The washes were spotted on
slides, and then the air-dried smears were stained with
haematoxylin. The slides were examined under a micro-
scope to determine the phase of the oestrous cycle. The
different stages of the oestrous cycle were determined
according to the predominant cell type present in the vagi-
nal smears by light microscopy [16]. Normal oestrous
cyclicity was defined as the occurrence of at least two con-
secutive normal oestrous cycles lasting for 4–5 days with
1–2 days of oestrus. The cycle length was defined as the
number of consecutive days between the oestrus smears in
the previous and the subsequent cycles.Histological study and follicle counting
Bilateral rat ovaries were taken after observation of the
oestrous cyclicity and fixed in 4% paraformaldehyde
overnight. Then, the ovaries were embedded in pa-
raffin and cut into 5-μm serial sections to be stained by
haematoxylin and eosin (HE). Every tenth section (50
slices in average per ovary) was selected for observation
under a light microscope (IX71, Olympus Optical Co.
LTD, Japan). The scoring system offered by Sağsöz et al.
[17], was used for histopathological evaluation of the ovar-
ian tissues, with some modifications. The histological
sections were examined for the presence of haemorrhage,
cortical fibrosis, follicular atresia and blood vessel damage.
The changes were scored from 0 to 3 according to their se-
verity, where 0 represents no pathological finding, and 1, 2,
and 3 represent pathological findings of < 33%, 33–66%,
and > 66% of the ovary, respectively. The scores for each
parameter were summed and the total scores were
calculated. The follicles were classified into three stages as
follows: primordial, growing (primary and secondary) and
mature follicles. A primordial follicle contains a partial or
complete layer of flattened granulosa cells encircling the
oocyte. In the primary follicle, the oocyte is surrounded by
a single layer of cuboidal granulosa cells. The secondary
follicle contains multiple layers of cuboidal granulosa cells
surrounding the oocyte with little or no antral space. A ma-
ture follicle contains a single large antral space adjacent tothe oocyte. The summation of follicles in different stages
was calculated for analysis.
Statistical analysis
SPSS 11.0 (SPSS Inc., Chicago, Illinois, USA) was used for
statistical analysis. One-Way ANOVA was performed to
analyse the quantitative data followed by the LSD-t test for
multiple comparison. Categorical data were analysed by the
Kruskal-Wallis test, and multiple comparisons were per-
formed using the Mann–Whitney U test. All tests of sig-
nificance were two-sided, and the significance value was
set at <0.05, whereas α’ was adjusted to 0.0017 in the
Mann–Whitney U test.
Results
Combination pretreatment completely prevented
gonadotropin flare-up
Serum levels of E2 during pretreatment in the six groups
are shown in Figure 1. GnRHant and both combination
treatments significantly decreased the E2 level on day 3
compared to the control group (P<0.001), and GnRHa
treatment slightly increased the E2 level. On day 5, the
E2 level in the GnRHa group decreased. On day 8, all
four treated groups had lower levels of E2, compared
with the control group (P<0.001). Moreover, the com-
bination (lng) group presented a significantly decreased
level of E2 compared to that in either the GnRHa or
GnRHant groups (P<0.001). No significant change was
observed in FSH level. LH level significantly increased in
the GnRHa group on day 3 compared with the other five
groups (P<0.001). A detailed description of the FSH, LH
and E2 levels in different groups at different time points
is given in Table 1.
Combination pretreatment partly restored oestrous cyclicity
Figure 2 shows the percentage of animals with nor-
mal, prolonged or irregular cycles. There were significant
differences in the distribution of the different types of
cyclicity between the groups (P<0.001). Rats in the con-
trol group all showed normal (4–5 days) oestrous cycles,
while treatment with CDDP significantly induced either
irregular oestrus or a prolonged cycle length that was
more than 7 days in the majority of the animals (58.3%)
(P<0.001). This cyclic change could be partly reversed by
pretreatment with GnRHa, GnRHant or a combination
of both. The percentage of normal cyclicity increased
from 0% to 25.0%, 33.3%, 66.7% and 41.7%, respectively.
Compared to the CDDP group, the combination (lng)
group showed a significantly altered distribution of
cyclicity (P<0.001). No such significance was found in
the GnRHa, GnRHant or the combination (sht) group,
but there were more (50%) rats experiencing a slight-
ly prolonged cycle (5–7 days) in the GnRHa group
(PGnRHa=0.007, PGnRHant=0.029, Psht=0.010).
Figure 1 Serum gonadotropin levels. The average E2 levels during pretreatment in the control, GnRHa, GnRHant combination (lng) and
combination (sht) groups. Blood samples were taken on the 1st, 3rd, 5th and 8th day. **P<0.01, compared with the control group; ##P<0.01,
compared with the combination (lng) group.
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follicles
The follicles at different stages were observed under a light
microscope. In the control group, the number of follicles at
various stages was present and the layers of surrounding
granulosa cells were integral. In the CDDP group, the fol-
licle structure was destroyed, resulting in a remarkable re-
duction in number. Obvious damage including cortical
fibrosis, follicular atresia and blood vessel damage induced
by cisplatin was significantly different from that in control
group (P<0.001, See Additional file 1: Figure S1). None of
the pretreatments could rescue the tissue damage. MoreTable 1 Hormonal levels during the course of GnRH analogue

























































































aP<0.01 vs. control group; bP<0.01 vs. combination (lng) group.
Data are expressed as the mean ± standard error.primordial follicles were reserved in other groups despite
the pathological changes mentioned above (Figure 3A).
The follicles in each stage were counted, as shown in
Figure 3B, and the detailed numbers are listed in Table 2.
The differences between groups in primordial, growth and
mature follicles were significant (P<0.001). CDDP induced
a significant reduction of primordial, growing, mature and
total follicles compared with the control group (P<0.001),
and 63.2% of the primordial follicle pool was lost. The
GnRHa, GnRHant, combination (lng) and combination
(sht) groups showed significant protection of the primor-
dial follicles from destruction, with preservation of 57.6%,pretreatment



































































































Figure 2 Oestrous cyclicity. The percentage of animals experiencing normal, prolonged or irregular cycles in the control, CDDP, GnRHa,
GnRHant combination (lng) and combination (sht) groups. The numbers in the column indicate the numbers of rats.
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the differences between the combination (lng) group and
the single pretreatment groups or the combination (sht)
group were also significant (P<0.001). The reduction of the
growing and mature follicles was not reversed except in the
GnRHant group, and the number of growing follicles inFigure 3 Ovarian histological study and follicle counting. Histological
morphology in the ovaries of rats in the control group; an obvious decline
group; a remarkable sparing of primordial follicles in the GnRHa group, the
follicle; PF—primary follicle; aPF—atretic primary follicle; SF—secondary fol
follicle counts of rats in the control, CDDP, GnRHa, GnRHant and combinat
compared to the CDDP group; §§ P<0.01, compared to the combination (lthe GnRHant group differed significantly from that in the
CDDP group.
Discussion
Chemotherapy decreases the mortality of cancer pa-
tients, but it is also associated with irreversible ovarianexamination of ovaries, 100×. Numerous follicles with normal
of follicles and the destruction of the ovarian structure in the CDDP
GnRHant group and both combination groups. Arrow—primordial
licle; aSF—atretic primary follicle (A). Primordial, growing, and mature
ion groups. **P<0.01, compared to the control group; ## P<0.01,
ng) group (B).
Table 2 Follicle count of bilateral ovaries in the 6 groups
Groups n Primordial follicle Growing follicle Mature follicle Total
Control 12 370.5±6.9 235.3±31.1 54.6±17.1 660±24.4
CDDP 12 136.5±23.1a 28.6±4.7a 9.1±6.3a 174.2±32.5a
GnRHa 12 213.2±22.3abc 41.6±12.3a 13±10.6a 267.8±34.2abc
GnRHant 12 227.5±8.9abc 71.5±12.0ab 19.5±6.8ab 318.5±6.9abc
aP<0.01 vs. control group; bP<0.01 vs. CDDP group; cP<0.01 vs. combination (lng) group; dP<0.05 vs. CDDP group.
Data are expressed as the mean ± standard error.
Li et al. Reproductive Biology and Endocrinology 2013, 11:16 Page 6 of 8
http://www.rbej.com/content/11/1/16toxicity [18,19]. Administration of a GnRH agonist has
been proposed to be a non-invasive method to protect
the ovarian reserve from chemotherapy, although the
efficacy of this approach is still controversial [8,13,19-25].
By suppressing the hypothalamic-pituitary-ovarian
axis, the GnRH agonist preserves more primordial
follicles, which are not vulnerable to chemotherapeutic
agents [9]. The recommended pretreatment before che-
motherapy requires approximately two weeks due to
the flare-up effect of gonadotropin concentration in the
first week. This flare-up effect is not acceptable in two
types of patients, including those suffering from rapidly
progressive cancer and who cannot wait for the initi-
ation of chemotherapy, and patients for whom an
elevated gonadotropin level may promote the progress
of some hormone-susceptible cancers such as breast
and ovarian cancer. GnRH antagonist, which is also
reported to act as a protective agent, rapidly down
regulates the gonadotropin level without flare-up effect,
but there are no long-acting GnRH antagonists avail-
able [9,11,26-29]. The combination of GnRH agonist
and antagonist treatment is assumed to have a rapid
long-acting suppression effect, avoiding the initial go-
nadotropin activation. Until now, four studies investi-
gating the combination of these drugs have reported
that the hormone changes are beyond those observed
using controlled ovarian hyperstimulation protocols.
Mardesic et al. reported a down regulation of LH 96 h
after the combination treatment, and von Woff et al.
found an incomplete reduction in the hormone flare-up
in the combination group [12,15]. Roth et al. and
Mueller et al. detected flare-up in both groups [13,14].
In our study, an increasing tendency was observed for
E2, LH and FSH on day 3, but only the level of LH
increased significantly. This outcome is possibly due to
either the concentration peak not being observed at the
right time or the animals that are not at the same stage
of estrous at the beginning of treatments. Co-treatment
with GnRHant in the long term or the short term sig-
nificantly prevented the hormone flare-up, and the go-
nadotropin level rapidly fell to a low level in 5 days.
This conflicting result could be attributed to differences
between human and rodents, the dosage and the ad-
ministration strategy. Rats have a higher concentrationof GnRH receptors in the ovary, and pituitary-ovarian
[19] desensitisation can be completed quickly; thus,
rats may show a different response to the treatment
compared to humans.
Another finding in our study was that the combination
(lng) treatment significantly preserved more primordial
follicles than observed in the GnRHa or GnRHant only
groups. Danforth et al. reported that in a murine model,
the antagonist did not protect ovaries from chemotherapy-
induced toxicity, and it even depleted primordial follicles
[30]. No such effect was observed in the present study, but
the antagonist preserved the follicles similarly to the agon-
ist. This result is consistent with other studies performed
using the antagonist [9,11,26-29]. The combination (lng)
treatment enhanced the protective effect, which was
confirmed by all of our results. The combination treatment
decreased the E2 serum concentration to 96.6±5.8 pg/ml
(mean±SD) on day 8, and in the GnRHa and GnRHant
groups, the E2 levels were 159.6±8.5 pg/ml and 151.9
±10.4 pg/ml, respectively. In addition, 80% of the rats in
the combination group resumed a normal oestrous cycle
within 10 days after chemotherapy, while in the GnRHa
and GnRHant only groups, 20% and 40% resumed a nor-
mal cycle, respectively. These results indicated that the
ovarian function was maximally suppressed and quickly re-
sumed with the combination treatment. Although Johnson
et al. report that the primordial follicle pool is renewable,
this characteristic remains to be confirmed [31]. Therefore,
quantitative measurement of follicles is the best way to
evaluate the potential fertility. Consistently, the combin-
ation treatment maximally preserved the primordial
follicles. The pregnancy rate was not examined because the
animals were all sacrificed for histological analysis. Never-
theless, the effect of the combination (sht) treatment was
not significantly different compared to that in the GnRHa
or GnRHant groups. The enhanced protective effect could
be attributed to the total dosage of the two drugs without
any calibration, or it could be related to the synergistic
reaction between them. Our work suggests two pos-
sible methods to rapidly and effectively protect the ova-
ry from chemotherapy-induced damage: one is to add
GnRHant in the short term; the other is to increase the
dosage of GnRHa. The underlying mechanism requires fur-
ther investigation.
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In summary, our study implies that the combination of
GnRH agonist with antagonist completely prevents the
gonadotropin flare-up, and this combination enhances
protection of the ovaries from cisplatin-induced gonado-
toxicity in rats. This study may provide evidence for the
application of a combination treatment to preserve fer-
tility in female patients requiring chemotherapy.Additional file
Additional file 1: Figure S1. Total tissue damage scores (mean,
standard error) were significantly different among groups (P < 0.001).
**P<0.01, compared with the control group.
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